{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:11:50Z","timestamp":1790737910815,"version":"4.1.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    People with schizophrenia are more likely to develop cannabis use disorder (CUD) and experience worse outcomes with use. Yet as cannabis is legalized for medical and recreational use, there is interest in its therapeutic potential.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    To conduct a systematic review summarizing the design and results of controlled trials using defined doses of THC and CBD in schizophrenia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Method:<\/jats:bold>\n                    A keyword search of eight online literature databases identified 11 eligible reports.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    One placebo controlled trial (13 stable patients without CUD) found that intravenous THC increased psychosis and worsened learning\/recall. Two reports of a functional magnetic resonance (fMRI) study of smoked or oral THC in 12 abstinent patients with schizophrenia and CUD found no change in symptoms and cognition, and an amelioration of impaired resting state brain function in areas implicated in reward function and the default mode network. One 4 week trial in acutely psychotic inpatients without CUD (mean age 30 y) found 800 mg CBD to be similarly efficacious to amisupride in improving psychosis and cognition. Two 6 week studies of CBD augmentation of antipsychotics in stable outpatients reported mixed results: CBD 600 mg was not more effective than placebo; CBD 1,000 mg reduced symptoms in a sample that did not exclude cannabis use and CUD. A brain fMRI and proton magnetic resonance spectroscopy study of single dose CBD in a sample that did not exclude CUD and cannabis use found that CBD improved symptoms and brain function during a learning\/recall task and was associated with increased hippocampal glutamate.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Discussion:<\/jats:bold>\n                    There is substantial heterogeneity across studies in dose, method of drug delivery, length of treatment, patient age, whether patients with cannabis use\/CUD were included or excluded, and whether patients were using antipsychotic medication.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    There is insufficient evidence for an effect of THC or CBD on symptoms, cognition, and neuroimaging measures of brain function in schizophrenia. At this time, research does not support recommending medical cannabis (THC or CBD) for treating patients with schizophrenia. Further research should examine THC and CBD in schizophrenia with and without comorbid CUD and consider the role of CBD in mitigating symptom exacerbation from THC.\n                  <\/jats:p>","DOI":"10.3389\/fpsyt.2021.694394","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T08:52:51Z","timestamp":1627030371000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["The Impact of THC and CBD in Schizophrenia: A Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Saeed","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneliu N.","family":"Stanciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Brunette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"B1","volume-title":"Introductory Textbook of Psychiatry","author":"Black","year":"2011"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/schbul\/sbn068","article-title":"Reward processing in schizophrenia: a deficit in the representation of value","volume":"34","author":"Gold","year":"2008","journal-title":"Schizophr Bull."},{"key":"B4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/schbul\/sbp148","article-title":"How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association","volume":"37","author":"Achim","year":"2011","journal-title":"Schizophr Bull."},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/0972-6748.196045","article-title":"Prevalence of comorbid anxiety disorders in schizophrenia","volume":"25","author":"Kiran","year":"2016","journal-title":"Ind Psychiatry J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1192\/bjp.187.4.306","article-title":"Cannabis use and misuse prevalence among people with psychosis","volume":"187","author":"Green","year":"2005","journal-title":"Br J Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/oxfordjournals.schbul.a033438","article-title":"Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups","volume":"26","author":"Mueser","year":"2000","journal-title":"Schizophr Bull."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1017\/S003329170700236X","article-title":"Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder","volume":"38","author":"Ringen","year":"2008","journal-title":"Psychol Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1600-0447.2001.00452.x","article-title":"Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder","volume":"104","author":"Sevy","year":"2001","journal-title":"Acta Psychiatr Scand."},{"key":"B10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jsat.2007.01.008","article-title":"Substance abuse and schizophrenia: pharmacotherapeutic intervention","volume":"34","author":"Green","year":"2008","journal-title":"J Subst Abuse Treat."},{"key":"B11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/schbul\/sbi027","article-title":"J. The environment and schizophrenia: the role of cannabis use","volume":"31","author":"Henquet","year":"2005","journal-title":"Schizophr Bull."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/schbul\/sbp031","article-title":"Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis","volume":"36","author":"Koskinen","year":"2010","journal-title":"Schizophr Bull."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1176\/appi.ajp.2015.15070907","article-title":"Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions\u2013III","volume":"173","author":"Hasin","year":"2016","journal-title":"Am J Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1136\/bmj.325.7374.1212","article-title":"Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study","volume":"325","author":"Arseneault","year":"2002","journal-title":"BM J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/add.12050","article-title":"Cannabis use and vulnerability for psychosis in early adolescence\u2013a TRAILS study","volume":"108","author":"Griffith-Lendering","year":"2013","journal-title":"Addiction."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-analysis of the association between the level of cannabis use and risk of psychosis","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr Bull."},{"key":"B18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1192\/bjp.bp.107.045740","article-title":"Association of cannabis use with prodromal symptoms of psychosis in adolescence","volume":"192","author":"Miettunen","year":"2008","journal-title":"Br J Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1360-0443.2004.00806.x","article-title":"Early adolescent cannabis exposure and positive and negative dimensions of psychosis","volume":"99","author":"Stefanis","year":"2004","journal-title":"Addiction."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/schbul\/sbq041","article-title":"Examining a cognitive model of persecutory ideation in the daily life of people with schizophrenia: a computerized experience sampling study","volume":"37","author":"Ben-Zeev","year":"2011","journal-title":"Schizophr Bull."},{"key":"B21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/schbul\/sbn135","article-title":"Psychiatric comorbidities and schizophrenia","volume":"35","author":"Buckley","year":"2009","journal-title":"Schizophr Bull."},{"key":"B22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1192\/bjp.bp.109.072249","article-title":"Psychosis reactivity to cannabis use in daily life: an experience sampling study","volume":"196","author":"Henquet","year":"2010","journal-title":"Br J Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1192\/bjp.bp.107.046375","article-title":"Effects of cannabis use on outcomes of psychotic disorders: systematic review","volume":"193","author":"Zammit","year":"2008","journal-title":"Br J Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/npp.2017.198","article-title":"US epidemiology of cannabis use and associated problems","volume":"43","author":"Hasin","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.biopsych.2016.01.011","article-title":"Human laboratory studies on cannabinoids and psychosis","volume":"79","author":"Sherif","year":"2016","journal-title":"Biol Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of \u0394-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J Psychopharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0091-3057(00)00201-X","article-title":"Different effects of nabilone and cannabidiol on binocular depth inversion in man","volume":"66","author":"Leweke","year":"2000","journal-title":"Pharmacol Biochem Behav."},{"key":"B32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","article-title":"Cannabis with high cannabidiol content is associated with fewer psychotic experiences","volume":"130","author":"Schubart","year":"2011","journal-title":"Schizophr Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","article-title":"Changes in cannabis potency over the last 2 decades (1995\u20132014): analysis of current data in the United States","volume":"79","author":"ElSohly","year":"2016","journal-title":"Biol Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/can.2017.0038","article-title":"A novel observational method for assessing acute responses to cannabis: preliminary validation using legal market strains","volume":"3","author":"Bidwell","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug","volume":"39","author":"Zuardi","year":"2006","journal-title":"Brazilian J Med Biol Res."},{"key":"B36","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J Clin Psychiatry."},{"key":"B37","volume-title":"Map of Marijuana Legality by State","author":"Solutions","year":"2021"},{"key":"B38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.7326\/M18-0810","article-title":"Risks and benefits of marijuana use: a national survey of US adults","volume":"169","author":"Keyhani","year":"2018","journal-title":"Ann Intern Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/02791072.2011.587700","article-title":"Who are medical marijuana patients? Population characteristics from nine California assessment clinics","volume":"43","author":"Reinarman","year":"2011","journal-title":"J Psychoact Drugs."},{"key":"B40","volume-title":"Canadian Addiction Survey (CAS): A National Survey of Canadians' Use of Alcohol and Other Drugs: Prevalence of Use and Related Harms: Detailed Report","author":"Adlaf","year":"2005"},{"key":"B41","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.drugpo.2013.08.010","article-title":"Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use","volume":"24","author":"Walsh","year":"2013","journal-title":"Int J Drug Policy."},{"key":"B42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/schbul\/sbr196","article-title":"Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity\u2014implications for diagnosis and ultra\u2013high risk research","volume":"38","author":"Wigman","year":"2012","journal-title":"Schizophr Bull."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/jcm10061303","article-title":"Efficacy of cannabidiol for \u03b4-9-tetrahydrocannabinol-induced psychotic symptoms, schizophrenia, and cannabis use disorders: a narrative review","volume":"10","author":"Bartoli","year":"2021","journal-title":"J Clin Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/jcm8071058","article-title":"The potential of cannabidiol as a treatment for psychosis and addiction: who benefits most? A systematic review","volume":"8","author":"Batalla","year":"2019","journal-title":"J Clin Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: a systematic review","volume":"74","author":"Bonaccorso","year":"2019","journal-title":"Neurotoxicology."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2045125319881916","DOI":"10.1177\/2045125319881916","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"9","author":"Davies","year":"2019","journal-title":"Ther Adv Psychopharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"112890","DOI":"10.1016\/j.psychres.2020.112890","article-title":"Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: a systematic review with a risk of bias assessment","volume":"286","author":"Ghabrash","year":"2020","journal-title":"Psychiatry Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.neubiorev.2016.11.012","article-title":"A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia","volume":"72","author":"Osborne","year":"2017","journal-title":"Neurosci Biobehav Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.12788\/cp.0002","article-title":"Cannabidiol for psychosis: a review of 4 studies","volume":"19","author":"Saeed","year":"2020","journal-title":"Curr Psychiatr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YCO.0000000000000596","article-title":"Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies","volume":"33","author":"Schoevers","year":"2020","journal-title":"Curr Opin Psychiatry."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Syst Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2014study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj."},{"key":"B54","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B55","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction","volume":"57","author":"D'Souza","year":"2005","journal-title":"Biol Psychiatry."},{"key":"B56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.schres.2014.04.033","article-title":"Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: effects of cannabis and THC","volume":"158","author":"Fischer","year":"2014","journal-title":"Schizophr Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2017.07.029","article-title":"Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: a pilot investigation","volume":"194","author":"Whitfield-Gabrieli","year":"2018","journal-title":"Schizophr Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)","volume":"32","author":"Hallak","year":"2010","journal-title":"Braz J Psychiatry."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry."},{"key":"B60","doi-asserted-by":"publisher","first-page":"614811","DOI":"10.3389\/fphar.2021.614811","article-title":"Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial","volume":"12","author":"Leweke","year":"2021","journal-title":"Front Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/npp.2017.209","article-title":"Clinical and preclinical evidence for functional interactions of cannabidiol and \u0394 9-tetrahydrocannabinol","volume":"43","author":"Boggs","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am J Psychiatry."},{"key":"B63","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/S0033291719003519","article-title":"Normalization of mediotemporal and prefrontal activity, mediotemporal-striatal connectivity may underlie antipsychotic effects of cannabidiol in psychosis","volume":"51","author":"O'Neill","year":"2020","journal-title":"Psychol Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/02698811211001107","article-title":"Cannabidiol modulation of hippocampal glutamate in early psychosis","volume":"32","author":"O'Neill","year":"2021","journal-title":"J Psychopharmacol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"B67","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry."},{"key":"B68","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/13651500310002986","article-title":"The use of the Simpson Angus Scale for the assessment of movement disorder: a training guide","volume":"7","author":"Hawley","year":"2003","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1176\/ps.39.11.1172","article-title":"How to examine patients using the Abnormal Involuntary Movement Scale","volume":"39","author":"Munetz","year":"1988","journal-title":"Psychiatric Serv."},{"key":"B70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","article-title":"Timeline follow-back. In: Litten R and Allen J, editors","volume-title":"Measuring Alcohol Consumption","author":"Sobell","year":"1992"},{"key":"B71","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/oxfordjournals.schbul.a006953","article-title":"Electrodermically nonresponsive schizophrenia patients make more errors in the Stroop Color Word Test, indicating selective attention deficit","volume":"28","author":"Lopes-Machado","year":"2002","journal-title":"Schizophr Bull."},{"key":"B72","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.schres.2007.05.029","article-title":"Functional disintegration in paranoid schizophrenia using resting-state fMRI","volume":"97","author":"Zhou","year":"2007","journal-title":"Schizophr Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1073\/pnas.0809141106","article-title":"Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia","volume":"106","author":"Whitfield-Gabrieli","year":"2009","journal-title":"Proc Nat Acad Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1002\/hbm.20820","article-title":"Alterations in functional activation in euthymic bipolar disorder and schizophrenia during a working memory task","volume":"30","author":"Hamilton","year":"2009","journal-title":"Hum Brain Mapp."},{"key":"B76","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1192\/bjp.bp.110.083600","article-title":"Neural correlates of cognitive impairment in schizophrenia","volume":"199","author":"Ortiz-Gil","year":"2011","journal-title":"Br J Psychiatry."},{"key":"B77","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.biopsych.2010.11.009","article-title":"Brain network connectivity in individuals with schizophrenia and their siblings","volume":"69","author":"Repovs","year":"2011","journal-title":"Biol Psychiatry."},{"key":"B78","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.schres.2011.03.010","article-title":"Functional resting-state networks are differentially affected in schizophrenia","volume":"130","author":"Woodward","year":"2011","journal-title":"Schizophr Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/schbul\/sbq079","article-title":"The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample","volume":"38","author":"Y\u00fccel","year":"2012","journal-title":"Schizophr Bull."},{"key":"B80","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/0269881118760662","article-title":"Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders","volume":"32","author":"Sami","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1017\/S0033291709005522","article-title":"The acute effects of synthetic intravenous [Delta] 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning","volume":"39","author":"Morrison","year":"2009","journal-title":"Psychol Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.psychres.2016.11.007","article-title":"Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program","volume":"247","author":"Abdel-Baki","year":"2017","journal-title":"Psychiatry Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther Adv Psychopharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/01.nmd.0000221289.54911.63","article-title":"Substance abuse and the management of medication nonadherence in schizophrenia","volume":"194","author":"Wilk","year":"2006","journal-title":"J Nerv Ment Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","article-title":"Blunted psychotomimetic and amnestic effects of \u0394-9-tetrahydrocannabinol in frequent users of cannabis","volume":"33","author":"D'souza","year":"2008","journal-title":"Neuropsychopharmacology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","article-title":"Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial","volume":"75","author":"Bhattacharyya","year":"2018","journal-title":"JAMA Psychiatry."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-019-0534-2","article-title":"Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis","volume":"9","author":"Wilson","year":"2019","journal-title":"Transl Psychiatry."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep31939","article-title":"Cannabis and tolerance: acute drug impairment as a function of cannabis use history","volume":"6","author":"Ramaekers","year":"2016","journal-title":"Sci Rep."},{"key":"B89","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00213-012-2915-6","article-title":"Acute effects of THC on time perception in frequent and infrequent cannabis users","volume":"226","author":"Sewell","year":"2013","journal-title":"Psychopharmacology."},{"key":"B90","doi-asserted-by":"publisher","first-page":"9791","DOI":"10.1007\/s00216-013-7412-1","article-title":"Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint","volume":"405","author":"Fabritius","year":"2013","journal-title":"Anal Bioanal Chem."},{"key":"B91","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised \u0394 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/jat\/32.7.470","article-title":"Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint","volume":"32","author":"Toennes","year":"2008","journal-title":"J Anal Toxicol."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.694394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T08:52:58Z","timestamp":1627030378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.694394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":92,"alternative-id":["10.3389\/fpsyt.2021.694394"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.694394","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"article-number":"694394"}}